Buy Retatrutide in Europe: Research Buyer Guide

Last updated

Quick answer for research buyers

Retatrutide, also known as GLP-3 or LY3437943, is a triple GLP-1/GIP/glucagon receptor agonist supplied by Peptra Labs as a 10 mg lyophilised research reagent, shipped from the EU with tracking, VAT included, and documented per batch in a public lab reports archive (batch GY035: 99.7% purity, third-party verified). It is for laboratory research only, not for human or animal use, and it is not an approved medicine anywhere.

Retatrutide or GLP-3? Same molecule, two names

You will see this compound sold and discussed under two names. Retatrutide is the international nonproprietary name; LY3437943 is Eli Lilly’s development code; GLP-3 is a nickname the research community adopted because the peptide agonises a third receptor, glucagon, in addition to the GLP-1 and GIP receptors that tirzepatide covers. There is no hormone called GLP-3. When you compare listings, treat “GLP-3”, “reta” and “retatrutide” as the same reagent and compare the things that actually differ: purity data, batch documentation, and where it ships from.

Why Peptra Labs for Retatrutide

Three reasons that can be checked rather than believed. The batch number on every vial maps to a published report in our lab reports archive, and that report links to the testing laboratory’s own verification page (for batch GY035: 99.7% purity, tested 20 March 2026). Orders ship from a warehouse inside the EU, so buyers in the EU pay no customs and receive tracked parcels in 2-5 working days. Prices are shown with VAT included, so the number on the product page is the number you pay.

What Retatrutide is

A synthetic 39-amino-acid peptide with a fatty-acid side chain, discovered at Eli Lilly and first described in Cell Metabolism in 2022. Its distinguishing feature is balanced activity at three receptors. In the laboratory it serves as the reference triple agonist: the natural comparator for tirzepatide (GLP-1/GIP) and semaglutide (GLP-1) in receptor pharmacology, energy-balance and glucose-homeostasis models. Our three-way comparison sets the receptor profiles side by side, and the Retatrutide reference hub collects every page we publish on it.

What the published evidence covers

Retatrutide has an unusually deep clinical literature for a research peptide. The 2023 phase 2 trial in the New England Journal of Medicine studied it in obesity; a parallel phase 2 trial in The Lancet studied type 2 diabetes; a 2024 phase 2a trial in Nature Medicine looked at metabolic dysfunction-associated steatotic liver disease; and the phase 3 TRIUMPH programme was running in 2026. None of that makes it a medicine: it is investigational, and the reagent supplied here is not the clinical product. For a research buyer the point is different: the mechanism is well characterised, so a laboratory can design against a known receptor profile.

Checklist before you buy Retatrutide in Europe

  • The batch number on the vial must match a published report you can open before you order.
  • The report should be verifiable on the testing laboratory’s own platform, not only as an image on the seller’s site.
  • Purity data belongs to one batch; a “typical CoA” is not evidence for the vial you receive.
  • Identity (mass spectrometry) and purity (HPLC) are different tests; look for both.
  • Shipping from inside the EU means no customs formalities; check where the parcel actually leaves from.
  • The listing must avoid claims about effects in humans; a seller who makes them is not selling a research reagent.

Legal status in the EU

Retatrutide is not a controlled substance in the EU and is not an authorised medicine in the EU, the UK or the US. It may be purchased and held as a laboratory reagent for research use only. It is not named on the WADA Prohibited List; the live list is the binding reference for athletes. Details, country by country, are in the peptide risk profile.

How this connects to the Peptra trust cluster

To evaluate a batch, start with the lab reports, read quality testing, and confirm the research policy. The product itself is here: GLP-3 (Retatrutide) 10 mg.

FAQ

Where can I buy Retatrutide (GLP-3) for research in Europe?

Peptra Labs supplies retatrutide as a lyophilised 10 mg research reagent, shipped from an EU warehouse to EU countries with tracking, VAT included, with per-batch lab reports published online. Research use only.

Is GLP-3 the same as retatrutide?

Yes. GLP-3 is an informal name for retatrutide (LY3437943), a triple GLP-1/GIP/glucagon receptor agonist. It is not a separate compound.

Is Peptra Labs Retatrutide for human use?

No. It is a research reagent for in-vitro laboratory work by qualified professionals; it is not a medicine and not for human or animal use.

Is retatrutide legal to buy in the EU?

It is not controlled and not an authorised medicine; it can be bought as a laboratory reagent for research use only.

What quality signals should a Retatrutide buyer check?

A batch number on the vial that maps to a published, third-party-verifiable report; identity and purity tested separately; EU shipping origin; and a listing free of claims about effects in humans.

Does Retatrutide ship with a Certificate of Analysis in the parcel?

Reports are published online per batch rather than printed in the parcel, so you can verify before ordering and confirm on the testing laboratory’s platform.

How is retatrutide different from tirzepatide?

Tirzepatide agonises GLP-1 and GIP receptors; retatrutide adds the glucagon receptor. See the full comparison of retatrutide, tirzepatide and semaglutide.

References

Newer
Buy Selank in Europe: Research Buyer Guide
Older Buy PT-141 in Europe: Research Buyer Guide